🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 67% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Tablet(s) Serving Size
Other Combinations Product Type
67% Evidence Coverage

Supplement Facts — Evidence Check

250 mg
✅ Within RDA (0.5× RDA of 550 mg) 📚 36 studies (Tier A: 1, B: 7)
RDA 550mg This product: 250mg UL 3500mg
250 mg
📊 Market median: 550.0mg (217 products) 📚 29 studies (Tier A: 0, B: 5)
This product: 250mg
📊 Market median: 500.0mg (9 products)
This product: 100mg

Other Ingredients

Dicalcium Phosphate Cellulose Sodium Croscarmellose Sodium Starch Glycolate Stearic Acid Silica Calcium Silicate Magnesium Stearate Maltodextrin Polyethylene Glycol Lecithin Sodium Citrate

Label Claims — Verification

All Other
All Other (99% of products) Structure/Function (78% of products) Nutrient (22% of products)

Target Groups

Children 4 or More Years of Age Adult (18 - 50 Years)

Product Information

📋 Directions for Use

SUGGESTED USE: As a dietary supplement, adults and children 12 or more years of age, 1 tablet one or two times daily or as directed by a health professional.

⚠️ Warnings & Precautions

Keep out of reach of children.

Additional Information

BRONSON LABORATORIES

Store at room temperature. Protect from light.

Lot No./Use By

No. 95A

10011619 EXP:01/2013

Made in USA

Product Details

UPC / SKU 7 16563 09501 7
DSLD Entry Date 2013-08-23
Product Type Other Combinations
Form Tablet or Pill
Brand Bronson
DSLD ID 25051
Data Updated 2026-04-11

Research Evidence

32 Research Sources
50 Avg Quality Score
19 Rct
7 Meta Analysis
3 Clinical Trial
2 Other
1 Systematic Review
B Greater Choline-Containing Compounds and Myo-inositol in Treatment-Resistant Versus Responsive Schizophrenia: A 1H-Magnetic Resonance Spectroscopy Meta-analysis
Meta Analysis Biological psychiatry. Cognitive neuroscience and neuroimaging 2024
B Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines
Meta Analysis The Journal of clinical endocrinology and metabolism 2024
B Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes
Meta Analysis The Cochrane database of systematic reviews 2023
B Effectiveness of inositol, metformin and their combination in women with PCOS undergoing assisted reproduction: systematic review and meta-analysis
Meta Analysis Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2022
B Effects of myo-inositol vs. metformin on hormonal and metabolic parameters in women with PCOS: a meta-analysis
Meta Analysis Irish journal of medical science 2023
B Inositol for subfertile women with polycystic ovary syndrome
Meta Analysis The Cochrane database of systematic reviews 2018
B Treatment of lean PCOS teenagers: a follow-up comparison between Myo-Inositol and oral contraceptives
Rct European review for medical and pharmacological sciences 2021
B The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios
Rct European review for medical and pharmacological sciences 2019
C Investigating the effect of combined use of selenium and Myo-inositol supplements on thyroid function and autoimmune characteristics in thyroid disorders: a systematic review and meta-analysis
Meta Analysis Expert review of endocrinology & metabolism 2024
C Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes - a randomized and open-label, placebo-controlled clinical trial.
Rct International journal of food sciences and nutrition
View all evidence for Inositol →

Compare Similar Products

View all Inositol products →